MIT Technology Review’s annual Innovators Under 35 list highlighted nine biotech innovators this year, including Paschal Kija, Xiao Yang, Sarah Grandinette, Yuancheng (Ryan) Lu, and Samuel King, each advancing life‑saving or transformative technology.
Key Takeaways
- Paschal Kija’s Mkanda Salama stops postpartum bleeding in 73% of women within 20 minutes at a cost of $70.
- Xiao Yang’s kirigami‑inspired electrodes are ultra‑small, flexible, and designed to minimize brain tissue damage.
- Sarah Grandinette’s team created a personalized gene‑editing therapy that treated a child with a rare genetic disorder, leading to a successful hospital discharge.
- Ryan Lu’s reprogramming therapy that reversed vision loss in aged mice is now in early human trials.
- Samuel King used generative AI to design bacteriophages that can replicate and infect bacteria, opening possibilities for new therapeutics and environmental cleanup.
| Metric | Value | Why it matters |
|---|---|---|
| Device cost | $70 | Affordable for low‑resource settings |
| Bleeding cessation rate | 73% | High efficacy in controlling postpartum hemorrhage |
| Time to stop bleeding | 20 minutes | Rapid intervention critical for maternal survival |
Paschal Kija’s Mkanda Salama: A Low‑Cost Solution to Postpartum Hemorrhage
Paschal Kija, 28, engineered the Mkanda Salama—literally “Safe Wrap” in Swahili—an inexpensive device aimed at treating postpartum hemorrhage, which accounts for about 29% of maternal deaths in Tanzania. In a clinical study, the wrap halted bleeding in 73% of women within 20 minutes, and the entire system costs only $70.
Xiao Yang’s Kirigami‑Inspired Brain Electrodes
At 34, Xiao Yang is developing ultra‑small, flexible electrodes that mimic the structure of neurons. Drawing inspiration from the Japanese art of kirigami, she has fabricated a honeycombed spiral‑basket sheet of electrodes that can be used to study brain cells in vitro. The design aims to reduce damage to surrounding brain tissue when implanted.
Sarah Grandinette’s Personalized Gene‑Editing Therapy for KJ Muldoon Jr.
Sarah Grandinette, 26, contributed to a team that created a gene‑editing therapy tailored to Kyle “KJ” Muldoon Jr., who was born in 2024 with a rare, potentially fatal genetic disorder. Grandinette engineered cells carrying KJ’s genetic variant, screened gene‑editing approaches, and tested promising candidates in mice and monkeys. KJ received his first dose at about seven months old, responded well, and was later discharged from the hospital. He is described as “doing pretty great.”
Ryan Lu’s Reprogramming Therapy for Age‑Related Vision Loss
Yuancheng (Ryan) Lu, 34, and colleagues published a 2020 study demonstrating that a reprogramming therapy could reverse vision loss in aged, blind mice. An almost identical version of this therapy is now being tested in humans with eye disease. Life Biosciences, the company developing the drug, administered the first dose to a volunteer in June.
Samuel King’s AI‑Designed Bacteriophages
Samuel King, 27, employed a generative AI model to generate new genetic blueprints for bacteriophages—viruses that infect bacteria. After printing the blueprints as strands of DNA, King observed that the AI‑designed viruses could replicate, burst from bacterial cells, and infect neighboring bacteria. While viruses are not alive, King hopes that AI‑designed life forms could eventually be harnessed for drug development or pollution remediation.
Why It Matters
The Innovators Under 35 list underscores how youthful ingenuity is driving tangible progress in biotechnology. From affordable maternal health solutions to cutting‑edge gene editing, reprogramming, and AI‑generated therapeutics, these breakthroughs illustrate the breadth of innovation that can translate into real‑world impact. As these technologies move from research to clinical and commercial stages, they promise to reshape patient care, reduce healthcare costs, and open new avenues for treating previously intractable conditions.
Frequently Asked Questions
Who is Paschal Kija and what is Mkanda Salama?
Paschal Kija is a 28‑year‑old inventor who created Mkanda Salama, a $70 device that stops postpartum hemorrhage in 73% of women within 20 minutes, addressing a major cause of maternal mortality in Tanzania.
How does Xiao Yang’s electrode design reduce tissue damage?
Yang’s electrodes are ultra‑small, flexible, and constructed with a honeycombed spiral‑basket structure inspired by kirigami, which mimics neuronal shape and aims to minimize disruption to surrounding brain tissue when implanted.
What was the outcome of the gene‑editing therapy for KJ Muldoon Jr.?
After creating cells with KJ’s genetic variant and screening gene‑editing methods, the therapy was tested in mice and monkeys. KJ received the first dose at about seven months old, responded well, and was discharged from the hospital, now described as “doing pretty great.”
How is the reprogramming therapy being tested in humans?
Life Biosciences is administering the therapy to volunteers with eye disease, following a 2020 study that showed the same approach could reverse vision loss in aged, blind mice.
What potential applications do AI‑designed bacteriophages have?
AI‑generated bacteriophages can replicate and infect bacteria, suggesting future uses in drug development or environmental cleanup by targeting specific bacterial populations.
Bottom Line
MIT Technology Review’s Innovators Under 35 list spotlights a diverse set of young biotech leaders whose work ranges from low‑cost maternal health devices to sophisticated gene editing and AI‑driven therapeutics. Their achievements demonstrate that breakthrough science can emerge from a mix of traditional experimentation and emerging computational tools, offering hope for more effective, accessible medical solutions worldwide.
Reporting based on: original source.
Comments
Post a Comment